<DOC>
	<DOCNO>NCT00006482</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine gemcitabine cisplatin treat patient refractory recurrent cancer cervix .</brief_summary>
	<brief_title>Gemcitabine Cisplatin Treating Patients With Refractory Recurrent Cancer Cervix</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity gemcitabine cisplatin patient refractory recurrent squamous cell carcinoma cervix . - Determine nature degree toxicity regimen patient . OUTLINE : This multicenter study . Patients receive cisplatin IV gemcitabine IV 1 hour day 1 8 . Treatment continue every 28 day absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 28-69 patient accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm refractory recurrent squamous cell carcinoma cervix fail local therapy consider incurable Must 1 prior chemotherapy regimen cervical cancer No 1 prior chemotherapy regimen ( single combination drug therapy ) , unless use radiosensitizer No prior chemotherapy recurrent persistent disease include retreatment initial chemotherapy Bidimensionally measurable disease Ineligible high priority GOG protocol PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Platelet count least low limit normal Absolute neutrophil count least 1,500/mm^3 Hepatic : Bilirubin great 1.5 time normal SGOT alkaline phosphatase great 3 time normal Renal : Creatinine great 2.0 mg/dL Other : Not pregnant Fertile patient must use effective contraception No significant infection No malignancy within past 5 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic therapy cervical cancer Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy cervical cancer recover No prior gemcitabine Endocrine therapy : At least 3 week since prior endocrine therapy cervical cancer Radiotherapy : At least 3 week since prior radiotherapy cervical cancer recover No prior radiotherapy 25 % marrowbearing area Surgery : At least 3 week since prior surgery cervical cancer recover Other : No concurrent amifostine protective reagent No prior anticancer therapy contraindicates study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
</DOC>